Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, Gaudilliere B, MacKenzie E T, Rousseau J, Scatton B
Departments of Biology, Laboratoires d'Etudes et de Recherches Synthélabo, Bagneux, France.
J Pharmacol Exp Ther. 1988 Dec;247(3):1211-21.
Recent studies have strongly implicated the excitatory neurotransmitter glutamate in the cascade of pathological mechanisms that cause neuronal loss after certain types of brain ischemia. The neurotoxic effects of glutamate are mediated, at least in global ischemia, via NMDA receptors. In the present study we have examined the effects of compounds that possess NMDA receptor antagonist properties (ifenprodil, SL 82.0715 [(+/-)-alpha-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]- 1-piperidineethanol] and 1-[1-(2-thienyl)cyclohexyl]piperidine) on the histological consequences of focal, as opposed to global, cerebral ischemia in both the rat and the cat. Ifenprodil (0.3-3 mg/kg i.v.) administered as a perfusion over 3 hr after occlusion of the feline middle cerebral artery reduced the volume of infarcted tissue (measured 4 days after occlusion) in a dose-related manner. At the highest dose a 42% reduction of infarcted volume was noted, essentially in cortical tissue. In an identical protocol, a derivative of ifenprodil, SL 82.0715, reduced the volume of infarction in a manner comparable to that described for ifenprodil. As SL 82.0715 possesses better p.o. bioavailability, this compound was also evaluated in the rat, again after middle cerebral artery occlusion. First administered 30 min after the induction of ischemia, SL 82.0715 (1 and 10 mg/kg p.o.) reduced infarction volume by 34 and 48%, respectively. The quantitative histology was performed 2 days after middle cerebral artery occlusion. The noncompetitive receptor antagonist, 1-[1-(2-thienyl)cyclohexyl]piperidine, administered (1 mg/kg i.p.) before the induction of focal ischemia, similarly and significantly decreased the final volume of infarction. As both ifenprodil and SL 82.0715 are noncompetitive antagonists of the NMDA receptor, two conclusions may be drawn from the present investigation. First, NMDA antagonism by ifenprodil and its derivative is an effective approach for tissue sparing in animal models of stroke and brain infarction. Second, these pharmacological observations provide evidence for the involvement of excitatory amino-acid induced-neurotoxicity in the evolution and consequences of focal cerebral ischemia.
最近的研究有力地表明,兴奋性神经递质谷氨酸在某些类型的脑缺血后导致神经元丧失的一系列病理机制中起作用。谷氨酸的神经毒性作用至少在全脑缺血中是通过NMDA受体介导的。在本研究中,我们研究了具有NMDA受体拮抗剂特性的化合物(艾芬地尔、SL 82.0715 [(±)-α-(4-氯苯基)-4-[(4-氟苯基)甲基]-1-哌啶乙醇]和1-[1-(2-噻吩基)环己基]哌啶)对大鼠和猫局灶性而非全脑性脑缺血组织学后果的影响。在猫大脑中动脉闭塞后3小时内以灌注方式给予艾芬地尔(0.3 - 3毫克/千克静脉注射),梗死组织体积(在闭塞后4天测量)呈剂量依赖性减少。在最高剂量时,梗死体积减少了42%,主要是在皮质组织。在相同的实验方案中,艾芬地尔的衍生物SL 82.0715以与艾芬地尔相似的方式减少了梗死体积。由于SL 82.0715具有更好的口服生物利用度,该化合物也在大鼠大脑中动脉闭塞后进行了评估。在缺血诱导后30分钟首次给药,SL 82.0715(1和10毫克/千克口服)分别使梗死体积减少了34%和48%。定量组织学在大脑中动脉闭塞后2天进行。非竞争性受体拮抗剂1-[1-(2-噻吩基)环己基]哌啶在局灶性缺血诱导前给药(1毫克/千克腹腔注射),同样显著降低了最终梗死体积。由于艾芬地尔和SL 82.0715都是NMDA受体的非竞争性拮抗剂,从本研究中可以得出两个结论。第一,艾芬地尔及其衍生物的NMDA拮抗作用是在中风和脑梗死动物模型中保护组织的有效方法。第二,这些药理学观察结果为兴奋性氨基酸诱导的神经毒性参与局灶性脑缺血的发展和后果提供了证据。